Prolonged intratumoral retention of 111In-NOTA-MNTC-EGF with t1/2 = 4.1 ± 0.5 days as well as significant dose-dependent tumor growth delay (up to 90% growth inhibition) after intratumoral administration of 111In-NOTA-MNTC-EGF (Rosenkranz et al., 2018) permits us to suggest the similar in vivo characteristics for this new MNT. Here, EGF is linked to neoplasm.